



(51) International Patent Classification:
A61K 38/49 (2006.01)

(21) International Application Number:
PCT/EP2011/073577

(22) International Filing Date:
21 December 2011 (21.12.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/426,236 22 December 2010 (22.12.2010) US

(71) Applicant (for all designated States except US): **IFOM FONDAZIONE ISTITUTO FIRCI DI ONCOLOGIA MOLECOLARE** [IT/IT]; Via Adamello 16, I-20139 Milano (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SIDENIUS, Nicolai** [DK/IT]; c/o Laboratorio Trasduzione del Segnale e Matrice Molecolare, IFOM istituto FIRCI di Oncologia Molecolare - Campus IFOM-IEO, Via Adamello 16, I-20139 Milano (IT).

(74) Agents: **CAPASSO, Olga** et al.; c/o De Simone and Partners SpA, Via Vincenzo Bellini, 20, I-00198 Rome (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: uPAR-ANTAGONISTS AND USES THEREOF

(57) Abstract: The invention relates to inhibitors of the urokinase-type plasminogen activator receptor (uPAR). The generated inhibitors are bivalent uPAR-ligands containing the receptor binding domains of the extracellular protease urokinase-type plasminogen activator (uPA) and of the extracellular matrix protein vitronectin (VN), in different configurations, linked by a scaffold. The present invention also refers to the above molecules for use as a medicament, in particular for treatment of cancer, and for diagnostic purposes.



WO 2012/085076 A1